X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, Pierre Fabre will access the development and global commercialization of Exarafenib, an investigational pan-RAF inhibitor, which is being evaluated in preclinical trial studies for the treatment of NRAS-mutated melanoma.
Lead Product(s): Exarafenib
Therapeutic Area: Oncology Product Name: Exarafenib
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: $30.5 million Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2024
Details:
Through the acquisition, XOMA will get access to KIN-2787 (exarafenib), which is a potent and selective investigational small molecule pan-RAF inhibitor that is being evaluated for the BRAF/NRAS-mutated advanced or metastatic solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 16, 2024
Details:
KIN-2787 (exarafenib) is an orally administered, potent and selective investigational small molecule pan-RAF inhibitor, designed to target BRAF Class II and Class III alterations, it is a potential treatment for NRAS mutation-positive melanoma.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
KIN-2787, is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kinnate Biopharma
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 21, 2023
Details:
KIN-2787 (exarafenib), is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
KIN-3248 is an irreversible, small molecule pan-FGFR inhibitor designed to address primary FGFR2 and FGFR3 oncogenic alterations, including those predicted to drive acquired resistance to current FGFR-targeted therapies.
Lead Product(s): KIN-3248
Therapeutic Area: Oncology Product Name: KIN-3248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
KIN-3248 is a small-molecule kinase inhibitor that target cancer-associated alterations in FGFR2 and FGFR3 genes, which are among the most commonly identified oncogenic drivers detected in solid tumor cancers.
Lead Product(s): KIN-3248
Therapeutic Area: Oncology Product Name: KIN-3248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
KIN-2787, a pan-RAF inhibitor, achieved meaningful exposures that were dose proportional and exceeded the predicted efficacious thresholds based on preclinical models. KIN-2787 cleared the predicted efficacious dose at 300 mg bid.
Lead Product(s): KIN-2787,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
KIN-2787 is an orally available, potent and selective small molecule pan-RAF inhibitor being evaluated in KN-8701, an ongoing Phase 1 global clinical trial in patients with solid tumors harboring BRAF alterations or who have NRAS mutant melanoma.
Lead Product(s): KIN-2787,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
KIN-3248 is an irreversible, small molecule pan-FGFR inhibitor designed to address primary FGFR2 and FGFR3 oncogenic alterations, including gatekeeper, molecular brake, and activation loop mutations observed in cancers.
Lead Product(s): KIN-3248
Therapeutic Area: Oncology Product Name: KIN-3248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
